NASDAQ:RXDX - Prometheus Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.25
  • Forecasted Upside: 43.08 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$22.54
▲ +0.89 (4.11%)

This chart shows the closing price for RXDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prometheus Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RXDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RXDX

Analyst Price Target is $32.25
▲ +43.08% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Prometheus Biosciences in the last 3 months. The average price target is $32.25, with a high forecast of $40.00 and a low forecast of $25.00. The average price target represents a 43.08% upside from the last price of $22.54.

This chart shows the closing price for RXDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Prometheus Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2021Stifel NicolausReiterated RatingBuyLow
5/14/2021Stifel NicolausReiterated RatingBuy$25.00N/A
4/13/2021Credit Suisse GroupInitiated CoverageOutperform$30.00N/A
4/13/2021SVB LeerinkInitiated CoverageOutperform$34.00N/A
4/13/2021Stifel NicolausInitiated CoverageBuy$25.00N/A
4/13/2021GuggenheimInitiated CoverageBuy$40.00N/A
4/6/2021Stifel NicolausInitiated CoverageBuy$25.00N/A
4/6/2021GuggenheimInitiated CoverageBuy$40.00N/A
4/6/2021SVB LeerinkInitiated CoverageOutperform$34.00N/A
4/6/2021Credit Suisse GroupInitiated CoverageOutperform$30.00N/A
2/9/2018Cantor FitzgeraldReiterated RatingHold$27.00Low
12/28/2017Cantor FitzgeraldSet Price TargetBuy$23.00Low
12/28/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$27.00Low
12/27/2017Cantor FitzgeraldDowngradeOverweight ➝ Neutral$23.00 ➝ $27.00Low
12/26/2017SunTrust BanksDowngradeBuy ➝ Hold$25.00 ➝ $27.00Low
12/26/2017LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
12/22/2017Cantor FitzgeraldSet Price TargetBuy$23.00High
12/22/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$27.00High
11/20/2017SunTrust BanksInitiated CoverageBuyN/A
11/14/2017Cantor FitzgeraldSet Price TargetBuy$23.00N/A
10/18/2017LADENBURG THALM/SH SHBoost Price Target$20.25 ➝ $31.00N/A
10/17/2017Cantor FitzgeraldSet Price TargetBuy$15.00N/A
10/12/2017JPMorgan Chase & Co.Reiterated RatingBuy$18.00 ➝ $20.00N/A
9/27/2017Cantor FitzgeraldReiterated RatingBuy$15.00Low
9/6/2017Cantor FitzgeraldReiterated RatingBuy$15.00Low
7/10/2017Cantor FitzgeraldSet Price TargetBuy$15.00Medium
6/22/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$27.00High
6/4/2017Cantor FitzgeraldSet Price TargetBuy$15.00High
5/15/2017Cantor FitzgeraldSet Price TargetBuy$15.00Low
4/28/2017Cantor FitzgeraldReiterated RatingBuy$18.00Low
11/30/2016Jefferies Financial GroupReiterated RatingBuy$20.00N/A
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$32.00 ➝ $20.00N/A
(Data available from 8/5/2016 forward)
Prometheus Biosciences logo
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
Read More

Today's Range

Now: $22.54
Low: $21.36
High: $22.62

50 Day Range

MA: $23.22
Low: $19.26
High: $29.65

52 Week Range

Now: $22.54
Low: $16.11
High: $30.64

Volume

29,125 shs

Average Volume

170,334 shs

Market Capitalization

$876.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Prometheus Biosciences?

The following sell-side analysts have issued research reports on Prometheus Biosciences in the last twelve months: Credit Suisse Group AG, Guggenheim, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for RXDX.

What is the current price target for Prometheus Biosciences?

4 Wall Street analysts have set twelve-month price targets for Prometheus Biosciences in the last year. Their average twelve-month price target is $32.25, suggesting a possible upside of 49.0%. Guggenheim has the highest price target set, predicting RXDX will reach $40.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $25.00 for Prometheus Biosciences in the next year.
View the latest price targets for RXDX.

What is the current consensus analyst rating for Prometheus Biosciences?

Prometheus Biosciences currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RXDX will outperform the market and that investors should add to their positions of Prometheus Biosciences.
View the latest ratings for RXDX.

What other companies compete with Prometheus Biosciences?

How do I contact Prometheus Biosciences' investor relations team?

Prometheus Biosciences' physical mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company's listed phone number is +1-858-2555959 and its investor relations email address is [email protected] The official website for Prometheus Biosciences is ignyta.com.